• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a thiadiazole derivative of the formula I: in which Y is O, S, CH2, SO or a direct bond; m is 0 to 4 and n is 1 to 4 provided that when Y is S, O or SO m is 1 to 4, and when Y is 0 or SO n is 2 to 4; R1 is H or (C1-10)alkyl; A is 3,4-dioxocyclobuten-1,2-diyl or C=Z in which Z is O, S, NCN, NN02, CHNO2, NCONH2, C(CN)2, NCOR2, NCO2R2, NSO2R2 or NR3 in which R2 is (C1-6)alkyl or (C6-12)aryl and R3 is H or (C1-6)alkyl; B is (C1-6)alkoxy, (C1-6)aikylthio or NR4R5 in which R4 and R5 are independently H, (C1-10)alkyl, C3-6(alkenyl), (C3-6)-alkynyl, (C2-6) (primary hydroxy)alkyl, (C2-6) (primary amino)alkyl or (C3-6)cycloalkyl or R4 and R5 are joined to form a 5- or 6- membered saturated ring optionally containing an additional O or NH: and the salts thereof.
    公开号:SU1037839A3
    申请号:SU792772852
    申请日:1979-05-24
    公开日:1983-08-23
    发明作者:Орегон Йеллин Тобиас；Майкл Мант Деррик
    申请人:Кемикал Индастриз Лимитед (Фирма)；Ай-Си-Ай Америказ,Инк (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to the preparation of thiadiazole derivatives, which are antagonists of the action of histamine on the receptor, H-2, and are withdrawn. gastric acid secretion.
    The physiologically active histamine compound, which is formed naturally in the body of the first stomach, during the development of its activity, is able to bind with some receptors, which are divided into two separate types. The first type is called H-1 receptor and histamine action on this receptor is blocked (or antagonized) by classical antihistamine drugs, such as mepyramine. The second type of histamine receptor is called the H-2 receptor, and the action of histamine on this receptor is blocked by drugs such as cimetidine. One result of this blocking is the action of histamine on the receptor. H-2 is the inhibition of gastric acid secretion, and the compound having this ability is therefore used to treat peptic ulcers and other diseases caused or exacerbated by gastric acidity,
    A known method for producing guanidines, based on the interaction
    -to
    where X is oxygen or sulfur;
    Y, A and P have the indicated meanings, are reacted with a compound of the general formula BH, where B has the indicated meanings /, followed by isolation of the desired product in free form or as a salt.
    In the compound of the indicated general formula (1) and in the subsequent compounds, although the double bonds in both side chains are in certain positions, other tautomeric ones are possible.
    The most preferred group of compounds includes the following:
    (3 cya o-2-methylisothioureido) ethylthiomethyl-5-guanidino-1,2,4-thiadiaeol;
    3 2- (2-cyano-3-methylguanidino) ethylthiomethyl3 5-guanidino-1,2,4-. -diadiazole;
    ZS2- (2-cyano-3-ethylguanidino) ethyl thiomethyl 0-5-guanidino 1 2,4-thiadiazole; ,
    3-C2-C2-cyano-3 - (2-hydroxyethyl) guanidino-ethylthiomethyl -3-guanidino-1, 2,4-thiadiazole;
    (2-nitroguanidino) ethylthiomethyl -: 5-guanidino-1,2,4-thiadiazole;
    S-alkylisothiuronium salts with ammonia or amines J.
    The aim of the invention is to obtain new thiadiazole derivatives with valuable pharmacological properties.
    The goal is achieved by a method for producing 1,2,4-thiadiazole derivatives of the general formula:
    Sn
    HI.
    x
    IT - "- CIS (vn-A-in H, N
    15
    where Y is a sulfur atom
    or sulfinyl; A - 3,4-dioxacyclobutene-1,2-diyl or a group of the formula C Z, where Z is oxygen or sulfur, or the groups NCN, NNO, CHNO2, NCONH2, NSO2R, where H 1 is lower alkyl; n is an integer of 1 or 2; In the group of the formula). in which hydrogen lower alkyl, hydroxyethyl, aminoethyl or R together with the adjacent nitrogen atom form a pyrrolidine ring, or their salts, which consists in that the compound of the general formula:
    CHz-T-CH2) rt-RH-L-X-CH3
     (3-methylthioureido) ethylthiomethyl-5-guanidino-1, 2,4-tyadiazole;
    1- {2 (5-guanidino-1,2,4-thiadiazol. -3-yl) methylthio ethylamino-l-methylamino-2-nitro-ylene;
    3 {2- 2-cyano-3- (2-aminoethyl) guanidino ethylthiomethyl-5 -guanidino-1, 2,4-thiadiazole;
    3 C2- (2-dianoguanidino) ethylthiomethyl 3-5-guanidino-1,2,4-thiadiazole; and acid addition salts thereof suitable for pharmaceutical use.
    Suitable for pharmaceutical use, the sour additive salt of the thiadiazole compound is a salt formed with hydrochloric, hydrochloric, phosphoric sulfuric, citric or maleic acids.
    The method can be carried out using an excess of BH, i.e. using an excess of the amine of the formula, if desired in the presence of a diluent or solvent, such as water, methanol, ethanol or pyridine. This process can be accelerated or completed by applying heat by, for example, heating to the boiling point of a diluent or solvent. The thiadiazole derivative obtained by the proposed method is a histamine antagonist .H-2 (histoins acting on the H-2 receptor), It inhibits the secretion of gastric acid in orranism of warm-blooded animals and, therefore, is used to treat peptic ulcers and other diseases caused by or aggravated by gastric acidity, such as acid from the soil. and gastrointestinal bleeding caused by trauma. The activity of this compound, as a histamine H-2 antagonist, can be demonstrated using standard tests / for example, by determining the ability of a compound of the general formula (1) to inhibit histamine-induced positive chromotropic reaction in the self-contracted right atrial of the guinea pigs or by determining the ability of this compound inhibit histamine-induced increase in cyclic adenosine monophosphate (AMP) (in the presence of phosphodiesterase as an inhibitor) in a suspension of free cells the current obtained from the envelope If Zist dogs stomach. The test of guinea pigs in the atrium was performed as follows. The right atrium of the guinea pig was suspended with (isometric) 1 g in a thermometer; a statically controlled bath () containing 25 ml of oxygenated (95% 5i COj) KreEs-HauseCeifc buffer (pH 7.4) in a volume of 25 ml. Atrial tissue was stabilized for one hour, during which it was washed 2-4 times. Individual contractions were recorded by means of a force displacement sensor using a strain gauge connecting device and instantaneous contraction speeds were recorded by means of a cardiotachometer. A control reaction was obtained at 1 μmol of histamine, then the fabric was washed three times and again equilibrated to the basic speed. After re-equilibration for 15 minutes, the test compound was administered to the desired final concentration. Ten minutes after administration of the test compound, histamine (1 µmol) was reintroduced and the response to histamine in the presence of an antagonist (test compound) was compared with the control response to histamine. The result of the test was expressed as a percentage of the control response to histamine. After this, the apparent dissociation constant of the histamine H-2 antagonist was determined by standard methods. All compounds showed activity during tests on the atrium of the guinea pig at a concentration of a bath equal to or lower than 10 µmol, and more active compounds showed complete inhibition of the response at a given concentration. Inhibition of gastric secretion; 9-acid acid can be demonstrated using standard tests. Scientific research institutes, for example, by determining the ability of compounds of the general formula (1), introduced by Intra. or by intragastric injection, or through the mouth, to inhibit the secretion of acidic gastric juice in animals such as rats, cats, or dogs that have a gastric fistula and which secretion of gastric juice is stimulated by the administration of a secretion enhancing drug such as pentagastrin or histamine. : The dog test was performed as follows. A pure hound breed (weighing 9–12 kg) with a chronic gastric fistula was fed to the females of dogs during the night on an empty stomach ad water. During this experiment, the dogs were kept in a slightly relaxed position. When studying the effect of the test compound in the intravenous injection, the fistula was opened, and after the absence of the main secretion was determined for a 30-minute period, continuous infusion was started by intravenous injection of the secretion enhancing drug (0.5 µmol / kg / h histamine or 2 µg / kg / h of pentagastria) in saline (15 ml / h). Samples of gastric acid were taken every 15 minutes. The volume of each sample, and 1 ml of this sample were measured with 0.1 N titrovers. NaOH until neutral to determine acid concentration. After a constant level of secretion was reached (1-2 hours), the test compound was administered in saline solution by intravenous injection, and samples of gastric acid were collected for a further 2-3 hours, during which continuous infusion of the secretion enhancing drug was not stopped. When studying the effect of the test compound, administered by intragastric injection, the absence of primary secretion factor was determined during the 30-minute period, the time period, and directly into the stomach, through a dosing swab inserted into the fistula, the test compound containing 25 ml of 0 was administered A 5% (w / v) aqueous solution of hydroxypropylmethylcellulose and a 0.1% (w / v) aqueous solution of Tween 80 (Tween is the trademark of the product). After an hour, the fistula reopened and, by intravenous injection, quickly started infusing secretion drug / as described. The sample volume and the concentration of gastric acid, similar to that described, were measured and the achieved level of secretion in a control animal in whose body only an inert diluent of the drug was administered by intragastric injection. In studying the effect of the test compound administered through the mouth, this compound was administered in the form of a gelatin capsule about 15 ml of water. After one hour, the fistula was opened and by intravenous injection they began to rapidly infect the secretion-enhancing drug. The sample volume was measured and the concentration of gastric acid was compared with the level of acid secretion in the control animal in which the compound was not administered. The results obtained from the atrial test suggest that the activity of these compounds is determined by testing in dogs. When tested on dogs, neither toxicity nor adverse effects of these compounds were found. 3 G-2 {2-Cyano-3-methylguanidino) ethylthiomethyl} -5-guanidino-1,2,4-thiadiazole did not cause any toxicity. when entering it through the mouth into the body of rodents with a dose of 300 mg / kg. The same compound was well tolerated by dogs when administered through a mouth dose of 100 mg / kg. The adiazole derivative obtained by the inventive method can be used in the form of a pharmaceutical composition containing a thiadiazole derivative in combination with a non-toxic diluent or carrier suitable for pharmaceutical use. This pharmaceutical composition may be formulated for oral administration, rectum, parenterally, or for local use, and for such applications, it may be made by known methods in the form of, for example, tablets, capsules, solutions or suspensions. in water or small, emulsions, dispersible powders; candles, sterile injectable solutions or suspensions in the form or oil, gels, ointment creams or lotion. Pharmaceutical composition intended for. mouth, rectum or parzntheral, along with the thiadiazole derivative of the general formula (1), may also contain one or more drugs selected from antacid or can be mixed with these drugs, for example, it may contain mixtures of hydrate oxide aluminum magnesium oxide hydrate; anti-pepsin compounds, e.g. pepstatype; other antagrists. histamine H-2, such as cimetidine; sound-healing medications, such as carbonoxolone or wisg salts, 1 anti-inflammatory agents, such as ibuprofen, indog metacin, naproxen or aspirin; prrstaglandins, such as 16, -1b-dimethylprostaglandin E; classical antihistamines (histamine H-1 antagonists), such as mepyramine or diphenhydramine; anticholinergic agents such as atropine or propetelin bromide; solubility-promoting substances, for example, diazepam, chlordiazepoxide, or phenylethylbarbituric acid. The pharmaceutical composition used for topical administration may contain, in addition to the thiadiazole derivative, one or more classical antihistamines (histamine H-1 antagonists), for example, mepyramine or diphenhydramine, and / or one or more sterile anti-inflammatory drugs such as fluorocinolone or triamycinolone . A composition intended for topical use may contain 1-10% (w / w) thiadiazole derivative. The preferred pharmaceutical composition is a composition suitable for oral administration in the form of a single dose, for example a tablet or capsule, containing 10-500 mg of a thiadiazole derivative, or a composition suitable for intravenous, subcutaneous or intramuscular injection in the form of, for example, a sterile injectable preparation containing 0., 1-10% (w / w) thiadiazole derivative. The pharmaceutical composition according to the invention is administered to the human body for treatment of peptic ulcers and other diseases caused or exacerbated by the acidity of the gastric juice, in the same manner as for cimetidine, and the activity of the thiadiazole derivative is taken into account for determining -dose. , regarding cimetidine activity. Thus, for example, when administering the drug through the mouth, each patient should receive a dose of thiadia-el derivative 15–1500 mg, and preferably 20–200 mg, or when administering the drug by intravenous, subcutaneous or intramuscular injection, each patient should receive a dose of this compound 1.5 -150 mg, preferably 5-20 mg, and this drug is administered 2-4 times per day. When administered into the body through the rectum, the dose of the thiadiazole derivative is almost the same as when administered through the mouth. This composition can be administered with less frequently in the body, if the content of the thiadiazole derivative in it is several times higher than the amount that is effective when the drug is administered 2-4 times a day Lr and mep -1. Pa. Crude 3- (2-aminoethyl) thiomethyl -5-guanidium but-1,2,4-thiadiazoloxylate (6 g) in water (180 ml), triethylamine (2.1 ml and a solution of dimethyl (cyanoimido) dicycarbonate ( 2.7 g) in ethanol (180 ml) is stirred at 70 ° C for one and a half hours. The solvent is evaporated under vacuum and the resulting oil is extracted with boiling ethanol (200 ml). To the extract is added an excess solution of left acid in ethanol and It is then evaporated in vacuo to give a red oil, which crystallizes when mixed with water (40 ml). The crystals are filtered and dried. It is also obtained as a result of 3-G2- (3-cyano-2-methylisotiou, reido) ethylthiomethyl} -5-guanidino-1,2,4-thiadiazoloxalate. 3- (2-Aminoethyl) thiomethyl-5-guanidino-1 , 2,4-thiadiazoloxalate), used as a starting material, can be obtained as follows. From chlorophenolamine and trichloromethane sulfenyl chloride, 5-chloro-3chloromethyl-1, 2,4-thiadiazole (b.p. 54 ° C at 2 mm) is obtained, which serves to obtain 5-chloro-3-methyl-1,2,4-thiadiazole . Sodium hydride (4.8 g of a 50% (w / w) dispersion in oil) freed from oil by washing with dehydrated petroleum ether (Art. Bale -100-1200 stirred while heating with dehydrated tert-butanol (200 ml) for 30 minutes until gas evolution ceases. Guamidine hydrochloride (9.6 g) is added, and after 10 minutes 5-chloro-3-chloromethyl -1,2,4-thiadiazole (8.5 d) and the resulting suspension is stirred for 20 minutes, the solid is removed from the resulting suspension by centrifugation, resulting in a solution of crude 3-chloromethyl-5-guanidium-1, 2,4-thiadiazole. Sodium methyl acetate (5.8 g) is dissolved in ethanol dried over magnesium (100 ml) and cooled to hydrochloride (Argon). inoethanethiol (, g), the mixture is stirred for 10 minutes and cooled to 5 C. A solution of 3-chloro-methyl-5-guanidino-1, 2,4-thiadiazole is added to this mixture for 10 minutes with external cooling, so that the temperature did not rise above 15 ° C. After 30 minutes the solid precipitate was filtered and the filtrate was acidified with a solution of oxalic acid in ethanol and until greater ne.proiskhodilo form a solid precipitate. This solid product, 3- (2-amino-ethyl) thiomethyl-5-uanidine-1, 2,4-thiadiazoloxalate, is filtered off, washed with a small amount of ethanol and dried. Example 2. A mixture consisting of (3-cyado-2-methylisothioureido) ethylthiomethyl-5-guanidino-1,2,4-thiadiazole (2.0 g) and a 33% (w / v) solution of methylamine in ethanol (80 ml) is stirred at 20 ° C for 18 hours. This reaction mixture is filtered and the filtrate is evaporated in vacuo until an oil is left, which is subjected to chromatographic separation in a column filled with silica gel, elution was carried out with ethanol: toluene in the ratio 1: 2 (v / v). The product 3-C2- (2-cyano-Z-methylguanidino) ethylthiomethyl-5-guanidino-1, 2 4-thiadiazole released on the ferch 60 F-254 adsorbent plate with elution with ethanol: toluene in a ratio of 1: 2 (about / about), have so-called 159-1b1 ° C and Sf value of 0.4. The spectrum of nuclear magnetic resonance in dimethyl sulfoxide dg using tetramethylsilane as an internal standard () shows the following lines (cf): 7.2 (HH, multiplet), 3.7 (2H, singlet), 3, .35 (2H, multiplet) and 2.7 (5H, multiplet). Example 3. A mixture comprising 3-chloromethyl-5-guanidino-1,2,4-3, iadiazole (19.1 g) and 2-aminoethanethiol hydrochloride (11.4 g) is stirred in ethanol (200 ml). Add 10.8 n. NaOH (20 ml), and the mixture is stirred for two h-Ases. The precipitated solid powder is filtered and washed with ethanol (200 ml), and the combined filtrates are treated with dimethyl (cyanoimido) dithiocarbonate (17, b g). After 10 minutes, a solid precipitate began to form. After one hour, this precipitated solid is filtered off, washed with ethONOL and dried at (0.2 mm)
    resulting in a (3-cyano-2-methylisothioureido) ethylthiomethyl 1-5-guanidino-1,2,4-thiadiazole, having so pl. 178-179 C (melting with decomposition).
    Suspension (3-cyano-2-methylisothioureido) ethylthiomethyl 3-5-guanidino-1, 2,4-thiadiazole (10 g) in ethanol / 200 ml is stirred and cooled to ice (external cooling). Methylamine is introduced into this suspension. (166 g) for 2 hours at such a rate that the temperature did not rise above 17 ° C during external ice cooling. After the introduction of 80 g of methylamine, it is all gone into solution. After four hours, the cooling ice bath was removed, and excess methylamine was evaporated overnight. The final volume is about 120 ml. The resulting product is filtered, washed with a small amount of ethanol, the moisture is filtered off with suction and dried at (0.3 mm) -. After recrystallization of this product from an aqueous solution of ethanol (in a ratio (V / V) of 1: 3), (2-cyano-3-methyl-hyyanidine) methylthiomethyl-5-guanidino - 1, 2, 4-thiadiazole with m.p. . 198199 c.
    3-Chloromethyl-5-guanidino-1,2,4-thiadiazole, used as a starting material, can be obtained as follows.
    Guanidine nitrate (244 g) is suspended in dimethylformamide (500 ml), dried over a molecular sieve, and sodium hydride is added in the form of a thick mass (58 g) (63% (w / w)) by weight in 30 min. -N
    LF. II
    C - -JLcH, CH2-S- (CH2) 2-NHC-UR2R The results are summarized in table 1. EXAMPLE 6 A solution of 3- (2-aminoethyl) thiomethyl 3-5-guanidino-1,2,4-thiadiazole (1.16 g) and dimethyl (methylsulfonylimido) dithiocarbonate (1.0 g ) in ethanol (14 ml), and a stream of argon is passed through this solution for 4 hours. The resulting solution is chromatographed using seven preparative Merch 60 F-254 silica gel plates (30x30 cm) by elution with a mixture of toluene: ethanol: ethyl acetate: ammonia (density 0.880) in the ratio 60:40: 20: 10 (v / v / v / v). Fractions with Sf value of 0.6 are selected and extracted with ethanol, the combined extracts are evaporated to dryness and the resulting solid product is recrystallized from ethyl) with external cooling in a cooling bath with an acetone: solid carbon dioxide mixture, so that the mass temperature is maintained at 25-30 C This mixture is stirred for 30 minutes at 25 ° C, then cooled to. 5-chloro-3-chloromethyl-1, 2,4-thiadiazole (84.5 g) is added to the mixture for 20 minutes with external cooling of 5-10. Further
    0 the mixture is stirred for
    20 min at 25 s and then pour it into water (5000 ml) and extracted with ethyl acetate (2 x 5000 ml). The upper layers combined together are extracted with 2N. hydrochloric acid (2 x 5000 ml) and the combined acid extracts are alkalinized with 2N. NaOH. The product is filtered, washed with water, dehydrated by suction- /
     nor, and then dried over Rlo, at a pressure of 1 mm, whereby H-chloromethyl-5-guanidino-1, 2,4-thiadiazole was obtained.
    Example 4. Having carried out the process in the same manner as described in the second part of Example 3, but using a WATER solution of ethylamine (70% (w / v) instead of a solution of methylamine), (2-cyano-3-ethylguanidino) ethylthiomethyl3- 50-guanidino-1,2,4-thiadiazole, recoverable as a salt formed with one molecule of oxalic acid, mp 139-l4b ° C.
    Example 5. The process is carried out as described in example 4, but using the appropriate amine instead of ethylamine in this way, the following compounds are obtained:
    BSN
    2t, 3
    acetate, resulting in a crude 3-C2- (2-methyl-sulfonyl-3-methylisothioureido) ethylthiomethyl j-5-guanidino-1, 2,4-thiadiazole with so pl. 120-122 ° C.
    This isothiourea (0.30 g) is dissolved in a mixture containing ethanol (9 ml), water (6 ml) and a solution of methylamine in ethanol (9 ml of a 33% (w / v) solution and stirred for 24 hours at room temperature. This solution is evaporated in vacuo to an oil, which is dissolved in hot ethanol (1.5 ml) and cooled. Thus, half a pound (2-methylsulfonyl-3-methylguanidino) ethylthiomethyl-5-guanidium-1, 2,4-thiadiazole with a melting point of 172-173 ° C.
    Example 7. A solution of sodium hydroxide (0.8 g) in ethanol (3 ml and water (2.5 ml) was added dropwise to a stirred mixture containing 3-chloromethyl-5-guanidino-1, 2.4- thiad, azole (1.91 g), and 3-aminopropanethiol hydrochloride (1.28 g) in ethanol (25 4p) at room temperature under nitrogen atmosphere. The resulting pale yellow suspension is stirred for 4.5 hours and kept overnight, treated with charcoal and filtered through diatomaceous earth, dimethyl - (N-cyanoimido) -dithiocarbonate (1.46 g) / is added to the filtrate / and the mixture is stirred at The mixture is poured into water (50 m and extracted with ethyl acetate (3x25 m. The combined organic extracts are washed with water (50 ml), dried (over magnesium sulfate), filtered and evaporated to dryness. The resin obtained after evaporation (3-cyano-2-methylisothiouredo) propylthiomethyl 3-5-guanidino-1, 2,4-thiadiazole, dissolved in ethanol (15 ml) and treated with ethanol-methylamine solution (30 ml of 30% (w / v) of the solution. The mixture was stirred at room temperature for 4 hours and left to stand. for three days This mixture is evaporated to dryness and the residual evaporation product is purified by preparative thin layer HPLC chromatography using Merch 60 F-254 plates by elution with ethyl acetate: ammonia i (density 0.88) in a ratio of 6: 1: 1 (v / v / v) This product is crystallized from an aqueous solution of acetone, whereby 3-C3- (3-cyano-2-methylguanidino) propylthiomethyl-5-guanidino-1,2,4-thiadi azole is obtained in the form of a white solid with mp 117- 120 C. Example 8. A mixture containing 3- C (2-aminoethyl) thiomethyl 35-guanidino-1,2,4-thiadiazole (obtained from 3-chloromethyl-5-guanidino-1,2,4-thiadiazole (1 , 9 g). As described) in ethanol (20 ml) to. 1,1-di- (methylthio) -2-nitroethylene (1.65 g) in methanol (50 ml), heated with reflux for eight hours This mixture is evaporated to dryness and the residual evaporation product is extracted with hot ethanol (50 ml). The ethanol solution is cooled, filtered and the filtrate is evaporated to dryness. The evaporation residue is mixed with methanol (5 ml) and the precipitate is crystallized from ethanol, whereby 1- {2- (5-guanidivo-1, 2,4-thiaziazol-3-yl-methylthio-2-ethylmino-3-methylthio-2-nitro-ethylene is obtained in the form of a mixture, in the form of a mixture of ethylthio-2-ethylmino-3-methylthio-2-nitroethyl, in the form of a mixture of methanol-2-ethyl-amino-3-methyl-2-nitroethylthio-2-nitro-ethyl-3-nitroethyl-2-nitroethyl-2-nitroethyl-2-nitroethylthio-2-nitroethylthio-2-nitroethylthio-2-nitrophenyl). solid matter (0.33 g). This solid is added to a 30% (w / v) solution of methylamine in ethanol (10 ml) and the mixture is stirred at 25 ° C for 16 hours. The product is filtered and washed ethanol (5 ml) whereby 1- {2-G (5-guanidino-1, 2,4-thiadiazol-3-yl) methylthio ethylamino J -1 -methylamino-2 -nitroethylene (0.16 g) is obtained with m.p. 152-156 ° C (melting with decomposition). Example 9. To a solution of sodium ethylate obtained from sodium hydride (50% (w / w) dispersion in oil, 0.384 g) in ethanol (20 ml) is added at 2-a1 Minoethanethiol hydrochloride (0.456 g) and 3-chloromethyl-5-guanidino-1, 2,4-thiadiazole (0.768 g). The mixture is stirred under O. in an atmosphere of argon for 2 hours and then Let this mixture be filtered and injected into a solution of 1,2-dimethoxycyclobutene-3, 4-dione (0.568 g) in dehydrated methanol: (10 ml). The resulting yellow-orange solution is filiged, the filtrate is evaporated to dryness and the residual evaporation product is mixed several times with dried anhydrous petroleum ether (b.p. 60-. Formed as a result, 1- {2- ( 5-guanidino-1,2,4, -nadiazol-3-yl) methylthioZethylamino-2-methoxycyclobutene-3, 4-dione is dissolved in a solution of methylamine in ethanol (33% (w / v) 10 mp) and stirred at room temperature overnight. The pale yellow solid precipitated is filtered off and Dry with air, resulting in a half-finish of 1- {2-15-guanidino-1, 2,4-thiadiazol-3-yl) methylthio ethylamino} -2-methylg1Mynocyclobuten-3, 4-dione (0.65 g) t .pl. (melting with decomposition) 238-239 ° C, Example 10. Pure 3-chloromethyl-5-guanidino-1, 2,4-thiadiazole L. (150 g) is stirred in ethanol (600 ml) and the hydrochloride 2- is added to the solution. aminoethanethiol (93 g). Then 18 n is added to this mixture. NaOH (92 ml), diluted with water (300 ml), for 30 min at 10-15 s. After 90 minutes, water (600 ml) was added and the solution was stirred for an additional 30 minutes, after which dimethyl- (N-cyanoimido) carbonate (107 g) was added. The resulting solution was stirred for 60 minutes and then an aqueous solution of methylamine (40% (w / w), 660 ml) was added. The mixture is stirred for 18 hours, and the product is separated by filtration and washed with ethanol: water in a ratio of 1: 1 (v / v), 2x250 ml (164 g, 67%). As a result of crystallization from a mixture of ethanol: water in a ratio of 3: 1 (v / v), H-C3- (2-cyano-3-methylguanidino) ethyl thiomethyl-5-guanidino-1,2,4-thiadiazole is obtained. pure 3-chloromethyl-5-guanidino ". . ° ± GT ± the starting material can be obtained as follows., Crude 3-chloromethyl-5-guanidino-1, 2, 4-thiadiazole (199 g) is stirred in 2N. hydrochloric acid (1 l) for 1 hour, the pH value was adjusted to 4 by entering 18 n. sodium hydroxide and diatomaceous earth (60 g) is added. The mixture is stirred for 1 hour, the activated carbon (40 g) is added and the mixture is stirred again for 1 hour. The mixture was filtered and the solid was washed with 2N. hydrochloric acid (2x80 ml). The pH of the combined extracts was adjusted to 8 by the addition of 18N. Hydrate of sodium oxide and a valuable 3-chloromethyl-5-guanidino-1, 2,4-thiadiazole are filtered and washed with water (157 g, 79%). Example 11. The repetition method described in Example 1 can be obtained as follows:, (CH2) 2-JAN-LB. the results are shown in Table. 2, .Table
    Recrystallized from ethanol.
    Note: 1 Product highlighted as 1.7
    oxalate. N 25.7, S 13.5t N 25.8, S 13; 1.
    Found,%: C 31.0; H 4.3
    C9H NjOS2l, 75 02H204 Calculated: С 30.7; H 4.2;
    15 1037839-2. NMR spectrum in d dimethyl sul-4. M.p. 120-122c after conversion: foxide using tetramethylsilane crystallization from ethyl acetate,
    as an internal standard5-. M.p. 159-16lc.
    (() has the following resonances ((f): 6. T. pl. 185-186 ° C after the switch 2, 76 (2H, triplet); 2,82 EF, sing-rationalization from methanol.
    (Pet); 3.35 (2H, multiplet); 3.71
    (2R, Siiglet); 7,12- and 7,5 (bN, mul-7. Re-crystallized from ethyplets) -onols.
     3. m.p. 184-186 With after perekris-8. Dedicated as monooctallization from ethanol. , lettuce, 0.3 ethanol, so pl. 169-172 C,
    权利要求:
    Claims (1)
    [1]
    METHOD OF PRODUCING DERIVATIVES OF 1,2,4-thiadiazoles of general formula (I) to Jalg / C = 1 W I
    H 2 N N- 1 - CHf-Y-CCHzIn-liH-AB where y represents a sulfur atom or sulfinyl;
    A-3,4-dioxacyclobutene-1,2-diyl or a group of the formula C = Z, where Z is oxygen or sulfur, or the groups NCN, NNOg, CHNO 2 , NCONH 2 , NSO 2 R 1 , where R 4 is lower alkyl ;
    h is an integer of 1 or 2;
    8 is a group of the formula NR 2 R 9 in which R 2 and R 3 are hydrogen, lower alkyl, hydroxyethyl, aminoethyl or R 2 and R and together with the atom form a pyrrolidine nitrogen ring, or their salts, which consists in the fact that the compound is common formula NgYa / c = H_ C1
    H 2 №CH 2 -Y- (CH 2) zr NH-AX-CH 3 wherein X - oxygen, or sulfur;
    ν Υ, A and P have the indicated meanings, are reacted with a compound of the general formula BH, where c has the indicated meanings, followed by isolation of the target product in free form or in the form of a salt.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1037839A3|1983-08-23|Process for preparing derivatives of 1,2,4-triadiazole
    SU1400509A3|1988-05-30|Method of producing n-|-bicyclic derivatives of 2-imidazoleamine or acid-additive salts thereof
    US6071935A|2000-06-06|Derivatives of 2-|-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
    AU608746B2|1991-04-18|5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups
    SU1400508A3|1988-05-30|Method of producing derivatives of arylthiazole
    RU2434851C1|2011-11-27|Cyclic n,n'-diarylthioureas or n,n'-diarylureas - antagonists of androgen receptors, anti-cancer medication, method of obtaining and application
    TW200932221A|2009-08-01|Imidazole carbonyl compounds
    KR850001858B1|1985-12-28|Process for preparing 2-guanidino-4-heteroarylthiazoles
    US4242351A|1980-12-30|Antisecretory oxadiazoles and pharmaceutical compositions containing them
    US5073574A|1991-12-17|Tetrazolyl substituted benzonitriles and anti-tumor use thereof
    SU1266472A3|1986-10-23|Method of producing |-7/3-3-|-h,3h-pyrrole-|-thiazole
    US4141899A|1979-02-27|4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
    US4338447A|1982-07-06|5-Guanidino-1,2,4-oxadiazoles
    RU2039051C1|1995-07-09|Derivatives of triazolylhydrazide and their pharmaceutically acceptable salts
    JP2650117B2|1997-09-03|N-heterocyclic alcohol derivatives
    US5753667A|1998-05-19|1-oxo-2- | pentylpiperidine derivatives, their preparation and their therapeutic application
    US6060472A|2000-05-09|Thiadiazole compounds useful as inhibitors of H+ /K+ atpase
    DE3825242A1|1989-02-09|Histidinylamino compounds substituted by sulphur-containing groups
    SU1151208A3|1985-04-15|Method of obtaining heterocyclocontaining phenylamidine derivatives or their acid-additive salts
    SU1322979A3|1987-07-07|Method of producing imidazolylphenylamidine derivatives or acid-additive salts thereof
    PT91198B|1995-03-01|PROCESS FOR THE PREPARATION OF DERIVATIVES | QUINOLINE
    CA3045887A1|2018-06-14|Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
    KR850000060B1|1985-02-15|Process for preparing amidines
    SU1272978A3|1986-11-23|Method of producing guanidine derivatives or their salts with maleic acid
    PT89749B|1994-03-31|PROCESS FOR THE PREPARATION OF ALCANOYL AND AROYL-OXAZOLONES WITH TONICARDIACA ACTION
    同族专利:
    公开号 | 公开日
    AU4711479A|1979-11-29|
    PL118387B1|1981-09-30|
    ES480894A1|1980-02-01|
    HU179492B|1982-10-28|
    JPS54160376A|1979-12-19|
    AU529253B2|1983-06-02|
    IE790902L|1979-11-24|
    US4242350A|1980-12-30|
    IE48221B1|1984-10-31|
    PT69651A|1979-06-01|
    NO791710L|1979-11-27|
    US4332949A|1982-06-01|
    ES484150A1|1980-04-16|
    IL57388D0|1979-09-30|
    EP0006679B1|1982-07-21|
    CA1124729A|1982-06-01|
    CS207791B2|1981-08-31|
    DE2963363D1|1982-09-09|
    AT1353T|1982-08-15|
    PL215764A1|1980-06-16|
    FI791656A|1979-11-25|
    GR73611B|1984-03-26|
    DK209079A|1979-11-25|
    NZ190448A|1980-12-19|
    ZA792202B|1980-05-28|
    EP0006679A1|1980-01-09|
    DD143772A5|1980-09-10|
    CS207790B2|1981-08-31|
    ES484149A1|1980-04-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE842346C|1950-10-14|1952-06-26|Joachim Dipl-Chem Dr Goerdeler|Process for the preparation of 5-amino-1, 2, 4-thiodiazoles|
    DE955684C|1953-10-14|1957-01-10|Bayer Ag|Process for the preparation of 5-amino-1, 2, 4-thiodiazoles|
    NL266116A|1960-06-22|
    GB1305549A|1969-10-29|1973-02-07|
    BE758146A|1969-10-29|1971-04-28|Smith Kline French Lab|AMIDINE DERIVATIVES|
    GB1338169A|1971-03-09|1973-11-21|Smith Kline French Lab|Ureas thioureas and guanidines|
    GB1400319A|1972-04-20|1975-07-16|Smith Kline French Lab|Pharmaceutical compositions|
    GB1398426A|1972-09-05|1975-06-18|Smith Kline French Lab|Heterocyclic substituted guanidines|
    GB1397436A|1972-09-05|1975-06-11|Smith Kline French Lab|Heterocyclic n-cyanoguinidines|
    GB1421999A|1973-02-08|1976-01-21|Smith Kline French Lab|Heterocyclic containing sulphoxides|
    GB1419994A|1973-05-03|1976-01-07|Smith Kline French Lab|Heterocyclicalkylaminotheterocyclic compounds methods for their preparation and compositions comprising them|
    GB1421792A|1973-05-17|1976-01-21|Smith Kline French Lab|Heterocyclic substituted-1, 1-diamino-ethylene derivatives methods for their preparation and compositions containing them|
    GB1497260A|1974-06-28|1978-01-05|Smith Kline French Lab|Guanidine derivatives|
    GB1533380A|1974-09-02|1978-11-22|Smith Kline French Lab|Process for the preparation of heterocyclic substituted thioureas and h-cyanoguanidines|
    GB1533379A|1974-09-02|1978-11-22|Smith Kline French Lab|Process for the preparation of heterocyclic substituted ureas|
    GB1531231A|1974-09-02|1978-11-08|Smith Kline French Lab|Process for the production of cyanoguanidine derivatives|
    GB1574214A|1976-03-11|1980-09-03|Smith Kline French Lab|Amidines|
    US4165378A|1977-04-20|1979-08-21|Ici Americas Inc.|Guanidine derivatives of imidazoles and thiazoles|
    ZA782129B|1977-04-20|1979-03-28|Ici Ltd|Hertocyclic derivatives|
    EP0006679B1|1978-05-24|1982-07-21|Imperial Chemical Industries Plc|Antisecretory thiadiazole derivatives, processes for their manufacture and pharmaceutical compositions containing them|EP0006679B1|1978-05-24|1982-07-21|Imperial Chemical Industries Plc|Antisecretory thiadiazole derivatives, processes for their manufacture and pharmaceutical compositions containing them|
    DE3069889D1|1979-01-18|1985-02-14|Ici Plc|Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them|
    GR71929B|1979-11-13|1983-08-19|Ici Ltd|
    US4375547A|1980-10-02|1983-03-01|Eli Lilly And Company|N-Methyl-N'-2--4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine|
    EP0059597B1|1981-02-27|1986-04-23|Imperial Chemical Industries Plc|Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity|
    CA1233818A|1981-03-09|1988-03-08|David J. Gilman|Guanidine derivatives as histamine h-2 receptorantagonists|
    CA1209998A|1981-03-09|1986-08-19|David J. Gilman|Amide derivatives as histamine h-2 receptorantagonists|
    US4460584A|1981-03-13|1984-07-17|Imperial Chemical Industries Plc|Nitrogen heterocycles|
    US4463005A|1981-03-18|1984-07-31|Imperial Chemical Industries Plc|Bicyclic guanidines|
    IN158869B|1981-03-18|1987-02-07|Ici Plc|
    US4451463A|1981-03-24|1984-05-29|Imperial Chemical Industries Plc|Alcohol derivatives|
    EP0065823A1|1981-05-13|1982-12-01|Imperial Chemical Industries Plc|Heterocyclic guanidines as histamine H-2 antagonists|
    US4390701A|1981-05-18|1983-06-28|Bristol-Myers Company|1-Amino-2-[3-propylamino]cyclobutene-3,4-dione|
    US4539316A|1981-05-18|1985-09-03|Bristol-Myers Company|Pyridine derivatives of 1,2-diaminocyclobutene-3,4-diones|
    US4546188A|1981-05-18|1985-10-08|Bristol-Myers Company|Substituted 1,2-diaminocyclobutene-3,4-diones|
    US4607105A|1981-05-18|1986-08-19|Bristol-Myers Company|3-cyclobutene-1,2-dione intermediates|
    US4522943A|1981-05-18|1985-06-11|Bristol-Myers Company|Chemical compounds|
    EP0067508B1|1981-05-18|1985-10-30|Imperial Chemical Industries Plc|Amidine derivatives|
    US4395553A|1981-05-18|1983-07-26|Bristol-Myers Company|Chemical compounds|
    US4526973A|1981-05-18|1985-07-02|Bristol-Myers Company|Chemical compounds|
    JPH058183B2|1984-06-01|1993-02-01|Ikeda Mohando Co|
    GB8419223D0|1984-07-27|1984-08-30|Hoechst Uk Ltd|Sulphamoylguanidine derivatives|
    WO2022034121A1|2020-08-11|2022-02-17|Université De Strasbourg|H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB2173778|1978-05-24|
    [返回顶部]